We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Roche bids for remaining Genentech stake.
- Abstract
The article provides information on the $44 billion bid of Roche Pharmaceutical Co. to take on the 44% of biotechnology jewel from Genentech Inc. It states that Roche is considered as the biggest pharmaceutical company in Switzerland and according to its chief executive Severin Schwan, his company will make sure that all the necessary steps to foster the innovative and unique science-driven culture of the biotechnology firm will be provided after their acquisition of the firm. Moreover, Genentech was responsible for generating biotech blockbusters such as Avastin for colon cancer and Herceptin for treating breast cancer. It further notes that Roche had acquired the majority of Genentech's shares in 1999 and is now looking forward to completing the acquirement of the biotechnology jewel soon.
- Subjects
SWITZERLAND; TENDER offers; GENENTECH Inc.; F. Hoffmann-La Roche Ltd.; PHARMACEUTICAL biotechnology; SCHWAN, Severin; BIOTECHNOLOGY research; BIOTECHNOLOGY transfer; PHARMACEUTICAL industry
- Publication
Nature, 2008, Vol 454, Issue 7203, p381
- ISSN
0028-0836
- Publication type
Article
- DOI
10.1038/454381a